Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Contributed by: Business Wire

Logo

Tags

Research

Other Health

Pharmaceutical

Oncology

Other Communications

Publishing

Clinical Trials

Science

Cardiology

Biotechnology

Communications

FDA

Health

birtamimab

More Like This

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena to Participate in Upcoming Healthcare Conferences

Prothena to Participate in Upcoming Healthcare Conferences

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025